TOKYO, May 14 (Pulse News Wire) – RIBOMIC Inc. (4591.T) reported operating revenue from grants and foreign exchange gains, along with impairment losses on fixed assets, for its fiscal fourth quarter ending March 31, 2026.
During the period from January 1, 2026, to March 31, 2026, the company recognized grant income of ¥39.2 million related to the Orphan Drug Designation (ODD) received for its cartilage dysplasia treatment drug umedaptanib pegol in May 2025. Additionally, due to the weakening yen, the company recorded a foreign exchange gain of ¥26,000.
However, cumulatively since April 1, 2025, the company has incurred a total foreign exchange loss of ¥98,000. Furthermore, based on the accounting standards for asset impairments, RIBOMIC recorded an impairment loss of ¥5.6 million on its fixed assets during the same period.
🟢 Confidence: High AI-translated content.